Key result
BMV yields superior long-term event-free survival in rheumatic mitral stenosis with favorable valve morphology.
Why the study?
Percutaneous Balloon Mitral Valvuloplasty has become the treatment of choice for severe pliable rheumatic Mitral Stenosis, but long-term outcomes and complication rates require comprehensive review.
Does Percutaneous Balloon Mitral Valvuloplasty improve outcomes in patients with severe pliable rheumatic Mitral Stenosis?
Does Percutaneous Balloon Mitral Valvuloplasty improve outcomes in patients with severe pliable rheumatic Mitral Stenosis?
Balloon Mitral Valvuloplasty is a safe and effective treatment for severe pliable rheumatic mitral stenosis, offering excellent immediate hemodynamic improvements and long-term event-free survival, particularly in patients with favorable valve morphology.
Percutaneous Balloon Mitral Valvuloplasty (BMV) was introduced in 1984 by Inoue who developed the procedure as a logical extension of surgical closed commissurotomy. Since then, BMV has emerged as the treatment of choice for severe pliable rheumatic Mitral Stenosis (MS). With increasing experience and better selection of patient, the immediate results of the procedure have improved and the rate of complications declined. When the reported complications of BMV are viewed in aggregate, complications occur at approximately the following rates: mortality (0–0.5%), cerebral accident (1–2%), mitral regurgitation (MR) requiring surgery (1.6–3%). These complication rates compare favorably to those reported after surgical commissurotomy. Several randomized trials reported similar hemodynamic results with BMV and surgical commissurotomy. Restenosis after MBV ranges from 4% to 70% depending on the patient selection, valve morphology, and duration of follow-up. Restenosis was encountered in 31% of the author's series at mean follow-up 9 ± 5.2 years (range 1.5–19 years) and the 10, 15, and 19 years restenosis-free survival rates were (78 ± 2%) (52 ± 3%) and (26 ± 4%), respectively, and were significantly higher for patients with favorable mitral morphology (MES ⩽ 8) at 88 ± 2%, 67 ± 4% and 40 ± 6%), respectively (P < 0.0001). The 10, 15, and 19 years event-free survival rates were (88 ± 2%, 60 ± 4% and 28 ± 7%, respectively, and were significantly higher for patients with favorable mitral morphology (92 ± 2%, 70 ± 4% and 42 ± 7%, respectively (P < 0.0001). The effect of BMV on severe pulmonary hypertension, concomitant severe tricuspid regurgitation, left ventricular function, left atrial size, and atrial fibrillation are addressed in this review. In addition, the application of BMV in specific clinical situations such as in children, during pregnancy and for restenosis is discussed. The transseptal technique is the most common technique used to perform BMV.
No takes yet. Share an insight, caveat, or question.
Nn Ananda Rika (2023) conducted a review in Mitral Stenosis. Percutaneous Balloon Mitral Valvuloplasty vs. Surgical commissurotomy was evaluated on Restenosis-free survival and event-free survival. Percutaneous Balloon Mitral Valvuloplasty is an effective treatment for severe pliable rheumatic mitral stenosis, with long-term event-free survival significantly higher in patients with favorable mitral morphology.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: